Diabetes and cardiovascular events in hypertensive patients
- PMID: 10334799
- DOI: 10.1161/01.hyp.33.5.1130
Diabetes and cardiovascular events in hypertensive patients
Abstract
To determine the relation of self-reported history of diabetes as well as baseline and in-treatment blood sugar to subsequent cardiovascular disease (CVD) in treated hypertensive patients, we assessed the experience of 6886 participants in a systematic treatment program. The presence or absence of a history of diabetes was known for all patients, who were then stratified into 3 groups according to blood sugar at baseline and in treatment (<6.11, 6.11 to 7.74, and >/=7.75 mmol/L). Some 7.4% of all patients reported history of diabetes, and the overall prevalence of blood sugar >/=7. 75 mmol/L was 7.7% and 10.4% at baseline and in treatment, respectively. Patients with a history of diabetes were 10 or 8 times as likely to have blood sugar >/=7.75 mmol/L at baseline (47.2% versus 4.5%) or in treatment (55.0% versus 6.8%), as were patients without history. During an average 6.3 years of follow-up, patients with history of diabetes had a cardiovascular event incidence 2-fold higher than those without history (20.8 versus 8.6/1000 person-years). Age-gender-adjusted CVD incidence rate but not non-CVD was twice as high in the highest compared with the lowest blood sugar stratum (baseline 16.6 versus 8.4/1000 person-years; in treatment 15.2 versus 8.2). Three separate models of Cox multivariate analysis revealed that history of diabetes (with no history as reference) had a greater association with CVD events (hazard ratio 2.37, 95% confidence interval 1.80 to 3.11) than did baseline (1.75, 1.31 to 2.33) or in-treatment blood sugar (1.55, 1. 19 to 2.02). Furthermore, in the presence of history of diabetes (2. 15, 1.58 to 2.92), neither baseline nor in-treatment blood sugar was independently associated with CVD risk. In the elevated (>/=7.75 mmol/L) in-treatment blood sugar group, the age-gender-adjusted rate of CVD events in frequent diuretic users (30.79/1000 person-years) was significantly higher than in moderate (13.34, P=0.004) and rare users (13.25, P=0.008). These data affirm that the coincidence of diabetes and hypertension is common, that evidence of diabetes substantially increases CVD risk, that self-reported history is a more powerful predictor of CVD events than any measure of blood sugar, and that CVD increases in hypertensive diuretic users who develop hyperglycemia even when blood pressure is well controlled.
Similar articles
-
Serum uric acid and cardiovascular events in successfully treated hypertensive patients.Hypertension. 1999 Jul;34(1):144-50. doi: 10.1161/01.hyp.34.1.144. Hypertension. 1999. PMID: 10406838
-
Association between cardiovascular outcomes and antihypertensive drug treatment in older women.JAMA. 2004 Dec 15;292(23):2849-59. doi: 10.1001/jama.292.23.2849. JAMA. 2004. PMID: 15598916
-
Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP).J Hypertens. 2000 Aug;18(8):1149-54. doi: 10.1097/00004872-200018080-00021. J Hypertens. 2000. PMID: 10954008 Clinical Trial.
-
[Cardiovascular risk and cardiometabolic risk: an epidemiological evaluation].G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):6S-17S. G Ital Cardiol (Rome). 2008. PMID: 18773746 Review. Italian.
-
Experiences from hypertension trials. Impact of other risk factors.Drugs. 1988;36 Suppl 3:9-20. doi: 10.2165/00003495-198800363-00005. Drugs. 1988. PMID: 3076127 Review.
Cited by
-
Use of lipid-lowering drugs and blood pressure control in patients with arterial hypertension.J Clin Hypertens (Greenwich). 2002 Jul-Aug;4(4):277-85. doi: 10.1111/j.1524-6175.2002.00499.x. J Clin Hypertens (Greenwich). 2002. PMID: 12147931 Free PMC article. Review.
-
Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes.Diabetologia. 2010 Jan;53(1):180-91. doi: 10.1007/s00125-009-1575-5. Epub 2009 Nov 6. Diabetologia. 2010. PMID: 19894030
-
Cacao liquor procyanidin extract improves glucose tolerance by enhancing GLUT4 translocation and glucose uptake in skeletal muscle.J Nutr Sci. 2012 May 31;1:e2. doi: 10.1017/jns.2012.2. eCollection 2012. J Nutr Sci. 2012. PMID: 25191549 Free PMC article.
-
Racial/Ethnic differences in medication uptake and clinical outcomes among hospitalized cardiovascular patients with hypertension and diabetes.Am J Hypertens. 2015 Jan;28(1):106-12. doi: 10.1093/ajh/hpu101. Epub 2014 Jun 5. Am J Hypertens. 2015. PMID: 24904026 Free PMC article.
-
Antihypertensive combination therapy in primary care offices: results of a cross-sectional survey in Switzerland.Int J Gen Med. 2014 Dec 9;7:549-56. doi: 10.2147/IJGM.S74023. eCollection 2014. Int J Gen Med. 2014. PMID: 25525383 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical